To receive POXEL information in real time, send a request to [email protected]
POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today publishes its cash and revenue for the second quarter and first half of 2022.
Next financial press release: First-half 2022 results, September 21, 2022.